Skip to main content
Signal8

CITY THERAPEUTICS, INC. (CTY)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

City Therapeutics Inc. logo

City Therapeutics Inc.

NASDAQ:CTYHealthcare
AH+0.00%$18.67
Close$18.67+2.30%
Mkt Cap$939.7M
Float45.55M
O/S50.33M
VOL215K sh
$ Vol$3.96M
RVOL0.64×
Inst Own-
Dilution
City Therapeutics Inc. logoNASDAQ:CTYAH$18.67+0.00%
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 202618.3018.8517.8818.67245,419
Nov 6, 202617.9518.9917.0018.25311,823
Nov 5, 202616.2817.3215.8117.07214,042
Nov 4, 202619.3720.0716.2216.41359,825
Nov 3, 202621.1221.1218.7719.09275,531
Nov 2, 202621.0822.6519.1920.88224,386
Oct 30, 202622.0722.2620.3720.71116,787
Oct 29, 202621.6322.3521.5422.14130,918
Oct 28, 202620.8922.0520.5021.65335,301
Oct 27, 202620.7921.5920.7020.86214,811
Oct 26, 202620.6221.3120.3020.79136,061
Oct 23, 202620.6221.1420.0320.77343,837
Oct 22, 202620.4120.8819.7520.77127,597
Oct 21, 202620.7821.6919.9720.43283,087
Oct 20, 202621.4421.5020.0020.83633,156
Oct 19, 202621.9422.0021.0321.46302,369
Oct 16, 202623.0023.8820.5022.401,406,423
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
InsiderTypeShares
ARCH Venture Partners XII, LLC profile photoARCH Venture Partners XII, LLCConversion of Derivative3.29M
ARCH Venture Partners XII, LLC profile photoARCH Venture Partners XII, LLCConversion of Derivative5.48M
ARCH Venture Partners XII, LLC profile photoARCH Venture Partners XII, LLCConversion of Derivative2.03M
ARCH Venture Partners XII, LLC profile photoARCH Venture Partners XII, LLCPurchase170.0K
NELSEN ROBERT profile photoNELSEN ROBERTConversion of Derivative3.29M
NELSEN ROBERT profile photoNELSEN ROBERTConversion of Derivative5.48M
Shareholders
0.0%
Institutional
(0)
6.6%
Insiderⓘ
(4)
57.2%
5%+ Owners
(4)
36.3%
Unattributed (incl. retail)ⓘ
Insider6.6%
5%+ Beneficial57.2%
Unattributed (incl. retail)36.3%
Sources: Form 4, 13D/13GO/S: 50.3M · checked 9 Nov 2026 · market-data provider
Insiders & Institutional Holders

Insiders

About

City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics.

The company is based in Cambridge, MA.

The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets.

Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease.

The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.

Key Metrics
Market Cap$939.70M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateOct 16, 2026
Shares Outstanding50.33M
Authorized Shares
Float45.55M
52-Week Range
Volume
Average Daily Volume333.02K
245.42K today vs 333.02K avg(-26%)

30d Avg

333.02K

60d Avg

333.02K

90d Avg

333.02K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...